Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2025 09:00 ET | Source: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such...
July 10, 2025 08:45 ET | Source: International Myeloma Foundation

The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research

STUDIO CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the 30th anniversary of the Brian D. Novis (BDN) Research Grant Program. To...
July 09, 2025 08:30 ET | Source: Sernova Biotherapeutics, Inc.

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon...
July 09, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 09, 2025 08:00 ET | Source: 4Bio Capital

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean...
July 09, 2025 07:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...
July 09, 2025 05:13 ET | Source: Research and Markets

Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035 | Gene Therapy Boom Fuels Demand, Regulatory Hurdles Challenge Growth in Gene Therapy Manufacturing

Dublin, July 09, 2025 (GLOBE NEWSWIRE) -- The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. The global Viral Vectors...
July 09, 2025 03:00 ET | Source: 4Bio Capital

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean...
July 09, 2025 02:00 ET | Source: Purespring Therapeutics

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...
July 08, 2025 08:50 ET | Source: FN Media Group LLC

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues...